The risk of venipuncture in newborn with severe hemophilia: Case report of a large elbow hemorrhage and literature review of compartment syndrome

Giuseppe Lassandro, Anna Amoruso, Valentina Palladino, Viviana Valeria Palmieri, Paola Giordano

Pediatric Section, Department of Biomedical Science and Human Oncology, University “Aldo Moro”, Bari, Italy

Abstract

Hemophilies are hemorrhagic congenital rare diseases. The gold standard of therapy in hemophilies is the intravenously replacement therapy. We can infuse intravenously plasma derived factors (FVIII for Hemophilia A and FIX for Hemophilia B) or recombinant products (i.e. clotting factor synthetically produced). Venipuncture is not a safe procedure in subjects with hemorrhagic diseases. It is considered an invasive technique with potential massive bleeding and it requires standardized procedures to prevent complications. Local pressure after the procedure (with eventually ice rest) must be always done. In case of bleeding a rapid replacement therapy must be conducted. A severe complication in hemophilia is compartment syndrome. We report a case of massive bleeding in a hemophiliic newborn after venipuncture and a literature review of compartment syndrome in hemophiliacs. The aim of this paper is to help physicians in the clinical management to prevent the evolution of a massive bleeding in compartment syndrome.

Introduction

Hemophilies are hemorrhagic congenital rare diseases. The lack, in plasma, of clotting factor VIII (FVIII) defines Hemophilia A instead the lack of clotting factor IX (FIX) causes Hemophilia B. Hemophilia A and B present an X-linked recessive genetic transmission. For this reason, males are sick and females, in the majority of cases, are healthy carriers. The incidence is respectively 1 per 5000 male births in Hemophilia A and 1 per 30000 male births in Hemophilia B. Hemophilies are categorized according to the plasma concentration of factors in: mild (5 to 40%), moderate (1 to 5%) and severe (<1%). Severe patients have predominantly spontaneous hemorrhages instead mild patients suffer of bleeding after trauma or surgery. Subjects with moderate hemophilia can exhibit a wide range of symptoms. The gold standard of therapy in hemophilies is the replacement therapy. Therapy on demand to stop a bleeding or prophylactic regimen to prevent hemorrhages. We can infuse intravenously plasma derived factors (FVIII for Hemophilia A and FIX for Hemophilia B) or recombinant products (i.e. clotting factor synthetically produced by pharmaceutical industry). In hemophilic patients the development of inhibitors is a possible complication related to the therapy. Inhibitors are antibodies against the clotting factors infused. In last years was approved an innovative molecule. Emicizumab, the first of the non-fator therapies to be licensed for patients with inhibitor, is a bispecific antibody that binds to both factor IXa (FIXa) and factor X (FX) and in doing so supports conformational changes that allows FIXa to activate FX in the absence of FVIII. Emicizumab may prevent hemorrhages in hemophilic people with inhibitors. The diagnosis of hemophilia is suspected in childhood for a positive family history or for the appearance of an early bleeding without a known cause. Large hemorrhages may occur in infants with hemophilia in injection sites for recurrent micro bleedings due to the difficulty to find an appropriate vein but, also, for the immature fragile vascular structure. Venipuncture in newborn with severe hemophilia is not a safe procedure. International guidelines for the management of hemophilia suggest to use small butterfly needles (23- or 25-gauges), avoid surgical techniques to isolate a vein (except in emergency) and apply pressure for 3–5 min after venipuncture. Uncontrolled venipuncture hemorrhage can be the cause of a serious complication: the compartment syndrome. In literature there are limited experiences of acute compartment syndrome (ACS) in hemophilic subjects. In this paper, we describe a newborn with severe hemophilia A who presented a serious volar arm bleeding post venipuncture. The early detection of the problem and the intensive treatment with recombinant FVIII could prevent the compartment syndrome.

Case Report

We report a case of a male newborn by Polish mother with family history of severe hemophilia (two maternal uncles). He was born from vaginal delivery at 40 weeks after a pregnancy uncomplicated. No data was available on clinical status of two mother’s brothers and on inhibitor appearance because she had lost contacts with her polish family. Physical examination of newborn was negative, no traumatic lesions related at delivery were detected. He was discharged on the third day with recommendation to contact regional treatment center for pediatric hemophilia (PHTC). After seven days his mother noted several bruises in the thoracic area of the infant. Parents carried him in a peripheral hospital without hemophilia section. In emergency room, in the suspicion of coagulation disorder, a venipuncture for blood exams was performed. The complete blood count was normal but coagulation studies revealed an isolated prolonged activated partial thromboplastin time. To investigate these results...
baby has been subjected at another venipuncture. Coagulation factors (VIII, IX, XI) and Von Willebrand study (antigen and activity) were measured. The detection of a very low plasma factor VIII level (<1%) confirmed the diagnosis of severe hemophilia A. Doctor of emergency room reaffirmed the indication at parents to contact as soon as possible a PHTC. Newborn was conducted after three days at PHTC. Here at the first observation he presented a swollen with vast ecchymosis on his right arm (Figure 1). He was hospitalized. Ultrasound investigation revealed a large muscle hematoma (45×39 mm) with signs of skin suffering. The Doppler study showed no alteration in the blood flow of the vessels. Patient was immediately treated with recombinant factor VIII for seven successive days. The hematoma was significantly reduced, necrotic areas of the skin were not recorded and the ultrasound examination never showed vascular pain. At discharge he started a prophylaxis program with recombinant FVIII three times a week. After two weeks he returned to the hospital for the physical examination and blood tests. The exam highlighted further clinical improvement without sequelae but blood exam revealed the appearance of inhibitor against factor VIII (100 BU). Prophylaxis was stopped for the inefficacy of replacement therapy. At last follow up (six months later) persisted inhibitor (89 BU) and the arm showed no injury (Figure 2). Doctors of PHTC proposed at parents to start prophylaxis, subcutaneously, with Emicizumab to protect against possible bleedings.

Discussion

The bleeding tendency associated with hemophilia A is proportional to the degree of factor VIII deficiency. Subjects with factor VIII level plasma inferior to 1% are affected by severe hemophilia A. They present spontaneous and traumatic (also for surgery) hemorrhages. Intra-articular bleedings (prevalently knee, ankle and elbow) are the typical locations of events in people with hemophilia. Repeated hemarthroses lead to joint damage. The main complication of hemophilic is, indeed, the chronic arthropathy. Arthropathy causes pain, functional impotence and in the final stages motor disability. Replacement therapy with factor VIII (plasma-derived or recombinant) stops bleeding. Periodic intravenous infusion (two or three times a week) depending on the therapeutic regimen according to drug used to prevent spontaneous hemorrhages and, so, it reduces the risk of arthropathy. Children with hemophilia received precociously these prophylactic therapeutic approaches (before two years old and after the first articular bleeding). Therefore veins must be treated with care, they are the lifelines for a person with hemophilia. Another complication of hemophilic subjects is the appearance of the inhibitor. Inhibitors are neutralizing antibodies against infused factor VIII. The development of them occurs in up to 33% of patients with severe hemophilia A, in 13% of those with non-severe hemophilia A. The cause of the development of inhibitors is related to genetic risk (type of mutations and family history of inhibitors) or non-genetic risk (intensive treatment at the first factor VIII exposure and probably the type of drugs). In the presence of an inhibitor (for the inefficacy of the replacement therapy) the risk of major morbidity and the cost of care increase substantially. Consequences of bleeding and the demands of treatment increase the disease burden on patients and their families, leading to reduced quality of life, financial stress, and strained relationships. Challenges in hemophilic newborns are different from those in older children and adults. In the newborn period are common intracranial hemorrhages for difficult deliveries, genital dripping for ritual circumcision and, mostly, venipuncture bleedings. Awareness of signs and symptoms and the treatment of complications play a key role in preparing appropriate care plans and implementing preventive programs. The management of hemophilic neonates must be under the strict surveillance of the hemophilic reference center. Physicians and nurse, expert in the field, may prevent events life-threatening. Venipunctures and other invasive procedures must be reduced or postponed if not necessary. Pricking a vein can be difficult due to the anatomical characteristics of the newborn and repeated attempts can cause...
can bleed.\textsuperscript{16} Guidelines suggest, always, to perform a local compression after the procedure even if is not evident a bleeding in progress. The application of ice before and after venipuncture (as recommended during vaccination practice) can be useful to determine vasoconstriction that reduces the risk of bleeding.\textsuperscript{17} The clinical surveillance must be ensure for at least 24–48 hours. At the first sign of bleeding, the replacement therapy with factor VIII must be acted promptly (eventually repeated after 12–24 hours). Sometimes hospitalization, due to the fragility of neonatal clinical conditions, can be helpful to obtain a stable venous access for therapies (avoiding more venipunctures) and to guarantee surveillance. If the bleeding is not immediately controlled, acute compartment syndrome may occur. ACS is a rare but potentially devastating complication after venipuncture in people with hemophilia.\textsuperscript{18} Uncontrolled hemorrhage may generate a critical interstitial pressure in the closed osseo-fascial compartment. The elevation of pressure causes microvascular compromise and a reduction in the perfusion gradient. This leads to ischaemia of the tissue within that compartment. ACS is considered a surgical emergency that requires timely evaluation and treatment. The first step in the management of a suspected compartment syndrome should be sufficient the substitution of clotting factors, which may help lower the compartment pressure. A late intervention of ACS develops irreversible tissue ischaemia with potentially disastrous neurological deficits, muscle necrosis, ischaemic contracture, infection, chronic pain and finally amputation and even death. The treatment of ACS is surgical: quickly removal of all circumferential dressings down to the skin, usually followed by open fasciotomy. There are no specific pre-operative guidelines for factor replacement levels during fasciotomy, but is appropriate to maintain a plasma factor VIII level around 100% as in all major surgery. Infection is a possible complication that can aggravate blood loss.\textsuperscript{9} There are limited experiences in literature of ACS in hemophilic subjects (Table 1). In 1977 Lancourt et al. observed, in 200 hemophilics, 34 episodes of bleeding into the hand and forearm. Fasciotomy was not performed in any of them but in six episodes of bleeding into the anterior muscles of the forearm was complicated by contracture, neuropathy, or both. For authors an early diagnosis with intensive replacement of the missing clotting factor was essential to avoid an irreversible damage.\textsuperscript{19} In 1989 Nixon et al. described a case of ACS post venipuncture in the arm in a three-month-old male infant with fever and irritability. The lack of a positive family history and the unusual clinical presentation of the patient had delayed the diagnosis of hemophilia. In the case described, ACS resolved with only clotting factor replacement without surgical decompression.\textsuperscript{20} In 1994 Dumontier et al. focused the evolution of ACS in 12 cases of

<table>
<thead>
<tr>
<th>Study, year</th>
<th>Population</th>
<th>Injury</th>
<th>Anatomic location</th>
<th>Management</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lancourt, 1977\textsuperscript{19}</td>
<td>200 Hemophilics, 34 cases of bleeding</td>
<td>Unknown cases bleeding</td>
<td>Hand and forearm</td>
<td>No fasciotomy</td>
<td>Complications in six (contracture, neuropathy or both)</td>
</tr>
<tr>
<td>Nixon, 1989\textsuperscript{20}</td>
<td>1 case of ACS in hemophilia</td>
<td>After venipuncture</td>
<td>Forearm</td>
<td>Clotting factor replacement; no fasciotomy</td>
<td>Resolved</td>
</tr>
<tr>
<td>Dumontier, 1994\textsuperscript{21}</td>
<td>12 cases of ACS in hemophilics</td>
<td>3 minor trauma; 9 no trauma</td>
<td>10 cases in forearm; 2 cases in hand</td>
<td>Clotting factor replacement; 1 case fasciotomy and clot removal on the 11th day; 1 case fasciotomy on the 3rd day, clot removal plus skin grafting on the 9th day</td>
<td>Sequelae and incomplete recovery in two cases</td>
</tr>
<tr>
<td>Rodriguez-Merchan, 2013\textsuperscript{21}</td>
<td>3 cases of ACS in hemophilia</td>
<td>1 Ulnar claw; 1 forearm contusion; 1 distal radius</td>
<td>Upper limb</td>
<td>Clotting fracture factor replacement; No fasciotomy</td>
<td>A case of irreversible damage</td>
</tr>
<tr>
<td>Watts, 2005\textsuperscript{22}</td>
<td>1 case of ACS in severe hemophilia A and inhibitor</td>
<td>After trauma</td>
<td>Forearm</td>
<td>Fasciotomy, blood transfusion recombinant factor VIII</td>
<td>Resolved</td>
</tr>
<tr>
<td>Kim, 2013\textsuperscript{22}</td>
<td>1 case of ACS in hemophilia A</td>
<td>No trauma</td>
<td>Volar forearm</td>
<td>Clotting factor replacement; Fasciotomy</td>
<td>Resolved</td>
</tr>
<tr>
<td>Abdelhalim, 2015\textsuperscript{23}</td>
<td>1 case of ACS in severe hemophilia A and inhibitor</td>
<td>No trauma, Strenuous exercise</td>
<td>Bilateral forearms</td>
<td>Clotting factor replacement; decompression; fresh frozen plasma; factor VIII inhibitor bypassing activity; skin graft</td>
<td>Resolved</td>
</tr>
<tr>
<td>Niblock, 2016\textsuperscript{24}</td>
<td>2 cases of ACS in mild hemophilia B and A</td>
<td>Post trauma</td>
<td>Thigh</td>
<td>Clotting factor replacement</td>
<td>Resolved</td>
</tr>
<tr>
<td>Jones, 2013\textsuperscript{25}</td>
<td>1 case of ACS in mild hemophilia B</td>
<td>Contusion</td>
<td>Thigh</td>
<td>Fasciotomy; blood transfusion; plastic surgeons; skin graft</td>
<td>Resolved</td>
</tr>
<tr>
<td>Reynolds, 2017\textsuperscript{26}</td>
<td>1 case of ACS in mild hemophilia B</td>
<td>Olecranon fracture</td>
<td>Forearm</td>
<td>Clotting factor replacement; Fasciotomy</td>
<td>Resolved</td>
</tr>
<tr>
<td>Baghdadi, 2019\textsuperscript{27}</td>
<td>1 case of ACS in severe hemophilia A</td>
<td>Post synovectomy</td>
<td>Knee</td>
<td>Clotting factor replacement; corticosteroids; fasciotomy</td>
<td>Resolved, no sensory or motor sequelae</td>
</tr>
</tbody>
</table>

ACS, acute compartment syndrome.
hemophils with hemorrhage in the upper limb. They, again, confirmed the importance of clotting factor replacement as first line therapy because fasciectomy and sequelae were linked with late diagnosis and therapy. In 2005 Watts reported a case of ACS in forearm after trauma in a patient with severe hemophilia A and high-titer factor VIII inhibitor. An emergency fasciectomy was performed and then bleeding was controlled with recombinant factor VIIa. Fasciectomy for compartment syndrome is safe in hemophilic patients with inhibitors, but only in experienced hands and with coordination between the surgeon and hematologist. Rodriguez-Merchan reported, in his experience of three cases with ACS until 2013, a case of irreversible damage. The author stressed the importance of an expert medical consultation because in his worst case ACS had likely started 4 days prior to seeking medical attention. In the same year Kim et al. reported a single case successful resolved with fasciectomy. In 2015 Abdelhalim et al. recorded a bilateral ACS due to hemorrhage for strenuous exercise. The easy tendency to bleeding is related to the presence of inhibitor and, obviously, to lack of prophylaxis with factor VIII. In 2016 Niblock et al. reported two cases of ACS as the first clinical sign to suspect hemophilia. The author reported subjects with mild hemophilia. They, as above written, can have severe bleeding only after trauma. This consideration, but for mild hemophilia B, was yet updated by Jones and Reynolds in two different papers. Synovectomy is a procedure to contrast chronic arthropathy. This report remarked two concepts: the importance of hemostatic coverage before and after surgery and the tissue fragility during arthropathy.

Conclusions

Compartment syndrome is luckily an uncommon complication in hemophilic patients. It occurs when a bleeding determines a critical increase in blood pressure within a confined osseo-fascial compartment. The subsequent decline in perfusion pressure can lead to irreversible tissue damage and necrosis. The first line therapy is the replacement therapy and, if there is no rapid improvement, a surgical fasciectomy is required. Our case in newborn with a positive outcome teaches some considerations. First of all, venipuncture is considered an invasive procedure with potential massive bleeding. Local pressure after the procedure (with eventually ice rest) must be always done. In case of bleeding a rapid replacement therapy must be conducted. The PTHT should be contacted to monitor the clinical evolution. In case of inhibitors, new non-substitutive approaches are available and should take in account to prevent bleeding. Hemophilic children and their caregiver must be accompanied on the treatment path and never abandoned to improve social quality of life and to reduce economic impact.

References


